About the Company
We do not have any company description for Lipocine Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LPCN News
Lipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With Obesity
(RTTNews) - Lipocine Inc. (LPCN) Thursday announced positive results from the Phase 2 study of its drug candidate LPCN 2401, showing significant improvement in body composition in participants with ...
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
NDAQ:LPCN) Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity ...
Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs
Lipocine hopes its obesity candidate LPCN 2401 could work alongside glucagon-like peptide-1 receptor agonists (GLP1-RAs) to ...
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
SALT LAKE CITY, March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary ...
Lipocine: LPCN 1148 Meets Primary And Hepatic Encephalopathy Endpoints In Phase 2 Study
(RTTNews) - Lipocine Inc. (LPCN) reported positive topline results from a Phase 2 clinical study of LPCN 1148 in patients with cirrhosis. The study met primary and Hepatic Encephalopathy endpoints.
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7% Reduced android fat (AF) by 4.1% ...
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024 SALT LAKE CITY, March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a ...
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024 SALT LAKE CITY, March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a ...
Lipocine Inc.: Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Lipocine Inc reports results for the quarter ended in December - Earnings Summary 07.03. Lipocine GAAP EPS of -$3.14 07.03. Lipocine Inc.: Lipocine Announces Financial Results for the Full Year ...
Loading the latest forecasts...